Antiplatelet Therapy in Secondary Stroke Prevention

Antiplatelet agents remain the cornerstone of secondary prevention for non-cardioembolic ischemic stroke. However, selecting the right agent, timing, and duration requires understanding both the underlying stroke mechanism and the evolving evidence from clinical trials.

Primary Antithrombotic Selection by Stroke Etiology

The choice of antithrombotic therapy depends on the presumed stroke mechanism:

Etiology Unknown or Pending Workup

When stroke etiology is not yet established, antiplatelet therapy is the default initial choice. This approach provides protection during the diagnostic workup while avoiding the bleeding risks of empiric anticoagulation. Aspirin is most commonly initiated, though dual antiplatelet therapy (DAPT) may be considered in high-risk patients (see below).

Small Vessel Disease & Large Artery Atherosclerosis

Antiplatelet therapy is first-line for atherosclerotic stroke. Short-term DAPT (21–30 days) is beneficial for minor stroke/high risk TIA (see DAPT section). Aggressive risk factor management (statins, BP control) is equally critical.

Cardioembolic Stroke

Anticoagulation—not antiplatelets—is indicated for atrial fibrillation, mechanical valves, and most cardioembolic sources. See the Anticoagulation topic for timing and agent selection.

Embolic Stroke of Undetermined Source (ESUS)

Embolic stroke of undetermined source (ESUS) describes non-lacunar cryptogenic strokes with an embolic pattern but no identified high-risk cardioembolic source or significant large artery disease. The hypothesis that many ESUS patients harbor occult atrial fibrillation or subclinical atrial cardiopathy led to several trials testing DOACs versus aspirin. However, all four major ESUS trials failed to show benefit of anticoagulation over antiplatelet therapy—and some showed harm.

Why Did ESUS Trials Fail?

• Heterogeneous population: ESUS is a diagnosis of exclusion encompassing multiple mechanisms (occult AF, atrial cardiopathy, aortic plaque, cancer, PFO), not all responsive to anticoagulation
• Low AF detection rates: Only ~10–15% of ESUS patients have AF detected on prolonged monitoring
• Bleeding harm: Anticoagulation increases bleeding without offsetting ischemic benefit in unselected ESUS
• Enrichment strategies insufficient: Even trials selecting for atrial cardiopathy markers (ARCADIA, ATTICUS) failed to show benefit

Current Recommendation

Antiplatelet therapy remains the standard of care for ESUS. Anticoagulation should be reserved for patients with documented atrial fibrillation or other specific indications. Prolonged cardiac monitoring (≥30 days) is recommended to detect occult AF, at which point anticoagulation becomes appropriate.

Patient Already on Antiplatelet Therapy: Switch or Continue?

A common clinical dilemma arises when a patient has a stroke while already taking an antiplatelet agent. Should you switch agents or continue the same therapy?

Current Evidence

There is no high-quality RCT evidence that switching antiplatelet agents after a breakthrough stroke improves outcomes compared to continuing the same agent. Most guidelines recommend:

• Optimize dose and compliance first
• Address modifiable risk factors (BP, LDL, smoking, diabetes)
• Consider alternative mechanisms for stroke (cardioembolic source, dissection, hypercoagulable state)

Clopidogrel Resistance Testing

For patients who had a stroke while on clopidogrel, two options exist:

1. P2Y12 Platelet Function Testing

• Measures actual platelet inhibition (e.g., VerifyNow P2Y12 assay)
• High on-treatment platelet reactivity (HPR) is associated with increased ischemic events
• Levels > 200 PRU are associated with either in adherence or reduced metabolism and inadequate platelet inhibition

2. CYP2C19 Genotyping

• Clopidogrel is a prodrug requiring CYP2C19 for activation
• Loss-of-function (LOF) alleles (*2, *3) reduce clopidogrel effectiveness
• ~30% of Caucasians and ~50–60% of East Asians carry at least one LOF allele
• The CHANCE-2 trial showed that in CYP2C19 LOF carriers, ticagrelor-aspirin was superior to clopidogrel-aspirin

Ticagrelor as an Alternative

Ticagrelor does not require CYP2C19 metabolism and provides more consistent platelet inhibition. Consider ticagrelor (with aspirin for 21–30 days, then monotherapy) in:

• Known CYP2C19 LOF carriers
• Breakthrough stroke on clopidogrel
• High-risk patients where reliable platelet inhibition is critical (after stenting)

Short-Term Dual Antiplatelet Therapy (DAPT)

Multiple landmark trials have established that brief DAPT (21–30 days) reduces early recurrent stroke in patients with minor ischemic stroke or high-risk TIA. The benefit is front-loaded in the first few weeks when stroke recurrence risk is highest.

CHANCE (2013) — The Foundation

The Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events trial randomized 5,170 Chinese patients with minor stroke (NIHSS ≤3) or high-risk TIA (ABCD² ≥4) within 24 hours:

• Intervention: Clopidogrel 300mg load → 75mg daily + aspirin 75mg for 21 days, then clopidogrel alone
• Control: Aspirin 75mg daily for 90 days

Results:

• Stroke at 90 days: 8.2% vs 11.7% (HR 0.68, p<0.001)
• NNT = 29 to prevent one stroke
• Moderate/severe hemorrhage: 0.3% vs 0.3% (no difference)

POINT (2018) — Longer DAPT, More Bleeding

The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke trial tested 90 days of DAPT in a more diverse population:

• Intervention: Clopidogrel 600mg load → 75mg daily + aspirin for 90 days
• Control: Aspirin alone for 90 days
• Randomized within 12 hours (earlier than CHANCE)

Results:

• Ischemic events: 5.0% vs 6.5% (HR 0.75, p=0.02)
• Major hemorrhage: 0.9% vs 0.4% (HR 2.32, p=0.02)
• Benefit concentrated in first 7–10 days; bleeding risk increased after day 21

Clinical Implication: POINT confirmed DAPT benefit but showed that extending beyond 21 days increases bleeding without additional ischemic benefit.

THALES (2020) — Ticagrelor Alternative

The Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death trial tested ticagrelor-based DAPT:

• Intervention: Ticagrelor 180mg load → 90mg BID + aspirin for 30 days
• Control: Aspirin alone for 30 days
• Included slightly more severe strokes (NIHSS ≤5) and high-risk TIA (ABCD² ≥6 or ≥50% stenosis)

Results:

• Stroke or death at 30 days: 5.5% vs 6.6% (HR 0.83, p=0.02)
• Severe bleeding (BARC 3–5): 0.5% vs 0.1% (HR 3.99)
• Intracranial hemorrhage: 0.4% vs 0.1%

Clinical Implication: Ticagrelor-aspirin is an effective alternative to clopidogrel-aspirin, particularly useful when clopidogrel resistance is a concern.

CHANCE-2 (2021) — Pharmacogenomics-Guided Therapy

This trial specifically enrolled patients with CYP2C19 loss-of-function alleles:

• Intervention: Ticagrelor 180mg load → 90mg BID + aspirin for 21 days
• Control: Clopidogrel 300mg load → 75mg daily + aspirin for 21 days

Results:

• Stroke at 90 days: 6.0% vs 7.6% (HR 0.77, p=0.008)
• Any bleeding: 5.3% vs 2.5% (more with ticagrelor)
• Moderate/severe bleeding: 0.3% vs 0.3% (no difference)

Clinical Implication: In CYP2C19 LOF carriers, ticagrelor-aspirin is superior to clopidogrel-aspirin. Consider genotyping or empiric ticagrelor use in populations with high LOF prevalence.

CSPS.com (2019) — Cilostazol-Based DAPT

The Cilostazol Stroke Prevention Study for Antiplatelet Combination tested cilostazol-based dual therapy:

• Intervention: Cilostazol 100mg BID + aspirin or clopidogrel
• Control: Aspirin or clopidogrel monotherapy
• High-risk non-cardioembolic stroke patients in Japan

Results:

• Recurrent ischemic stroke: 3% vs 7% (HR 0.49, p=0.001)
• Severe/life-threatening bleeding: 0.6% vs 0.9% (no significant difference)
• Trial stopped early for efficacy

Long-Term DAPT: Generally Not Recommended

While short-term DAPT is beneficial, prolonged dual antiplatelet therapy is not recommended for most stroke patients. The evidence consistently shows that extending DAPT beyond 21–30 days increases bleeding without additional ischemic benefit.

Key Evidence Against Long-Term DAPT

MATCH Trial (2004)

• Aspirin + clopidogrel vs clopidogrel alone for 18 months in high-risk stroke/TIA patients
• No reduction in ischemic events
• Significantly increased life-threatening bleeding (2.6% vs 1.3%)

SPS3 Trial (2012)

• Aspirin + clopidogrel vs aspirin alone in lacunar stroke
• No benefit for recurrent stroke
• Increased major bleeding and all-cause mortality
• Trial stopped early for harm

POINT Subanalysis

• Benefit of DAPT concentrated in first 7–21 days
• After day 21, bleeding risk exceeded ischemic benefit

Triple Antiplatelet Therapy: More is NOT Better

The intuition that "more antiplatelet agents = better protection" has been definitively disproven.

TARDIS Trial (2018)

The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke trial tested intensive triple therapy:

• Intervention: Aspirin 75mg + clopidogrel 75mg + dipyridamole 200mg BID for 30 days
• Control: Guideline therapy (clopidogrel alone or aspirin + dipyridamole)
• 3,096 patients with acute non-cardioembolic stroke/TIA

Results:

• Recurrent stroke/TIA severity: No difference (adjusted OR 0.90, p=0.47)
• Major or fatal bleeding: 3% vs 1% (HR 2.23, p=0.006)
• Intracranial hemorrhage: 1% vs <1% (HR 3.14, p=0.026)
• Trial stopped early for futility and harm

Other Key Antiplatelet Trials

PRoFESS (2008) — Aspirin-Dipyridamole vs Clopidogrel

• 20,332 patients with recent non-cardioembolic stroke
• Aspirin 25mg + ER-dipyridamole 200mg BID vs clopidogrel 75mg
• Recurrent stroke: 9.0% vs 8.8% (no difference)
• More bleeding, headache, and discontinuation with aspirin-dipyridamole
• Conclusion: Equivalent efficacy; clopidogrel better tolerated

SOCRATES (2016) — Ticagrelor vs Aspirin Monotherapy

• 13,199 patients with minor stroke or high-risk TIA
• Ticagrelor monotherapy vs aspirin monotherapy for 90 days
• Stroke/MI/death: 6.7% vs 7.5% (HR 0.89, p=0.07—not significant)
• Conclusion: Ticagrelor monotherapy not superior to aspirin; the benefit of ticagrelor requires combination with aspirin (as in THALES)

Antiplatelet Pharmacology Comparison